Circulating tumor cells as biomarkers in prostate cancer.
about
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerAbiraterone in prostate cancer: a new angle to an old problemA critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentCirculating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.Using circulating tumor cells to inform on prostate cancer biology and clinical utilityFunctional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic deviceTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Nanotechnology for enrichment and detection of circulating tumor cells.Label-free isolation of circulating tumor cells in microfluidic devices: Current research and perspectivesCirculating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.Circulating tumor cells in melanoma patientsDual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Noncoding RNAs as novel biomarkers in prostate cancer.Aptamer-enabled efficient isolation of cancer cells from whole blood using a microfluidic deviceInterdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin.Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.MET and VEGF: synergistic targets in castration-resistant prostate cancerMethylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.Biomarker development in the context of urologic cancersLack of evidence for increased level of circulating urothelial cells in the peripheral blood after transurethral resection of bladder tumors.Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.Isolation and characterization of circulating tumor cells in prostate cancer.Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancerMeasuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.Applications of microfluidics and microchip electrophoresis for potential clinical biomarker analysis.Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus.Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.Biomarkers in prostate cancer epidemiology.Multivalent DNA nanospheres for enhanced capture of cancer cells in microfluidic devices.New generation of ensemble-decision aliquot ranking based on simplified microfluidic components for large-capacity trapping of circulating tumor cells.
P2860
Q26796568-D0DA75C8-97E4-41F2-BFDF-32AA88EF7A65Q26828810-58DA96C2-1061-4E80-BA04-9D0CE726F5BBQ26862558-EB7F5D28-45A0-4739-A5C8-67AEC365D8C4Q27334654-6C9AE9AE-35CF-4B64-9BAC-20A24D137BF9Q28083261-C3A60DAC-4327-499B-9305-FFE9E8712E52Q28482878-1ABC2DE0-506F-4922-8FE9-63905BB05569Q30277291-29930EC7-7B23-45A4-A715-859A6C67D5EDQ30354652-FA8202E2-F45B-4EF2-A122-7CE16BFC205EQ30382502-0395C221-0296-4FC9-AE7D-1AD9FEAA3F77Q30444025-23B8BD04-0BCE-4C4A-BCC1-04666CDF622DQ30574916-98D0A976-3A03-4CCA-9914-601BAFAFE966Q31075758-3995D832-0E48-4029-A44D-CA3CFC1FE2DFQ33414769-C35C159F-1A60-475B-921C-77FC81A0BA35Q33621403-D9A908A1-10AB-4119-90EB-EB5D4C7974F3Q33820631-445F9E8C-A8D5-4261-BF37-1262D15B47DFQ34066371-BF913AD7-A665-4BD0-9745-35F9A2B978A1Q34069988-F758CF13-5454-4383-BC16-BAAB18D45E27Q34108738-A4EEB822-6252-4B6C-8ABD-077D3CC272BBQ34176890-37220B30-2209-4FAF-8285-11F86CAE91B5Q34223867-EC30BA3D-551C-4ED7-9D34-F305CC5DA8ABQ34894366-6FF3F2F9-60F2-4224-96ED-C6A889E6D247Q35252908-2D8CFDEB-2E63-4CD4-95FD-6ED7B7921BE5Q35575488-04FC57B5-F684-438A-8F86-B2490548CD44Q35678056-17A421F5-E263-4361-848E-C3ED0B5553E6Q35906352-BC9AFE8A-5DF5-4845-88F4-6CCDB1D5D0ADQ35981404-67ED25E8-520A-407E-9CB9-B2DC78EE998CQ36030759-835BF666-AC65-49FF-9621-145AF06CA87FQ36093582-48106EA2-B4F4-4A8F-8D9F-3AE77FEACF96Q36243296-B6362D53-CC62-4551-B818-1A40082EB0ECQ36310363-2AD942CC-ACF3-49CF-93B6-AA849E5CB997Q36339707-9A55B759-EA7A-4673-A178-55444610CE38Q36362489-A9951698-C273-44FB-B4F0-39D280BE9C20Q36429530-3131B63D-961F-4F50-9AA2-62FA33AAAD9EQ36496717-9EF30A4A-018A-46B3-B941-5379C25F7AC1Q36640843-81AD5F2E-360E-46AA-B85B-7AF1A54D7032Q36940245-2FC42307-8D6B-4951-9010-C75F8BE894C5Q36998629-58265BB8-0B84-467D-8BA9-9A72DAE46838Q37148139-2F10CAD8-E48E-4D8E-BBBD-3205A4FB1DB9Q37202667-6B674007-3A2B-48CC-8E18-DBBE585D162AQ37341244-BF450114-C90F-449E-A8DC-D518F9DBFB3A
P2860
Circulating tumor cells as biomarkers in prostate cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Circulating tumor cells as biomarkers in prostate cancer.
@ast
Circulating tumor cells as biomarkers in prostate cancer.
@en
Circulating tumor cells as biomarkers in prostate cancer.
@nl
type
label
Circulating tumor cells as biomarkers in prostate cancer.
@ast
Circulating tumor cells as biomarkers in prostate cancer.
@en
Circulating tumor cells as biomarkers in prostate cancer.
@nl
prefLabel
Circulating tumor cells as biomarkers in prostate cancer.
@ast
Circulating tumor cells as biomarkers in prostate cancer.
@en
Circulating tumor cells as biomarkers in prostate cancer.
@nl
P2093
P2860
P1476
Circulating tumor cells as biomarkers in prostate cancer.
@en
P2093
Daniel C Danila
Howard I Scher
Martin Fleisher
P2860
P304
P356
10.1158/1078-0432.CCR-10-2650
P407
P577
2011-06-01T00:00:00Z